CureVac’s Fate Hangs in the Balance as Shareholders Vote on BioNTech Takeover

CureVac NL0015436031

The independent existence of CureVac could soon be a chapter in corporate history. On November 25, shareholders will convene in Amsterdam for an extraordinary general meeting, facing a definitive vote on the German biotech firm’s future. The central item on the agenda is a proposed acquisition by rival BioNTech, valued at approximately $1.25 billion. The prevailing sentiment among market observers is not if the Tübingen-based company will be absorbed by its mRNA competitor, but when the transaction will be finalized.